Tags

Type your tag names separated by a space and hit enter

Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion.
Diabete Metab. 1986 Feb; 12(1):34-8.DM

Abstract

We have studied the effect of the combination of a sulfonylurea (Hb 420 or glibenclamide) with insulin in 22 type II diabetic patients, treated with insulin and with residual insulin secretion (fasting plasma C peptide level greater than 0.2 pmol/ml). After a 3 week run-in period, the patients received either glibenclamide (7 mg of Hb 420 before breakfast and 3.5 mg before supper) or placebo in double blind fashion. Clinical and biological parameters (body weight, number of hypoglycemic episodes, daily insulin dose, fasting and postprandial glucose and C peptide levels after a standard meal) were collected during the basal (run-in) period and after 8 and 16 weeks of treatment. In the glibenclamide group, a significant increase in the number of hypoglycemic episodes was observed in spite of a 8 to 10% reduction in insulin requirements. A 18% reduction of both fasting and postprandial plasma glucose levels was found after 8 and 16 weeks of glibenclamide therapy. Concomitantly, a 35% increase of fasting and postprandial plasma C peptide levels occurred. The data suggest that the use of combined sulfonylurea and insulin therapy may be beneficial to type II diabetic patients with residual insulin secretion and poor glycemic control under insulin therapy alone.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

3084315

Citation

Mauerhoff, T, et al. "Effect of Glibenclamide in Insulin-treated Diabetic Patients With a Residual Insulin Secretion." Diabete & Metabolisme, vol. 12, no. 1, 1986, pp. 34-8.
Mauerhoff T, Ketelslegers JM, Lambert AE. Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion. Diabete Metab. 1986;12(1):34-8.
Mauerhoff, T., Ketelslegers, J. M., & Lambert, A. E. (1986). Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion. Diabete & Metabolisme, 12(1), 34-8.
Mauerhoff T, Ketelslegers JM, Lambert AE. Effect of Glibenclamide in Insulin-treated Diabetic Patients With a Residual Insulin Secretion. Diabete Metab. 1986;12(1):34-8. PubMed PMID: 3084315.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion. AU - Mauerhoff,T, AU - Ketelslegers,J M, AU - Lambert,A E, PY - 1986/2/1/pubmed PY - 2000/3/11/medline PY - 1986/2/1/entrez SP - 34 EP - 8 JF - Diabete & metabolisme JO - Diabete Metab VL - 12 IS - 1 N2 - We have studied the effect of the combination of a sulfonylurea (Hb 420 or glibenclamide) with insulin in 22 type II diabetic patients, treated with insulin and with residual insulin secretion (fasting plasma C peptide level greater than 0.2 pmol/ml). After a 3 week run-in period, the patients received either glibenclamide (7 mg of Hb 420 before breakfast and 3.5 mg before supper) or placebo in double blind fashion. Clinical and biological parameters (body weight, number of hypoglycemic episodes, daily insulin dose, fasting and postprandial glucose and C peptide levels after a standard meal) were collected during the basal (run-in) period and after 8 and 16 weeks of treatment. In the glibenclamide group, a significant increase in the number of hypoglycemic episodes was observed in spite of a 8 to 10% reduction in insulin requirements. A 18% reduction of both fasting and postprandial plasma glucose levels was found after 8 and 16 weeks of glibenclamide therapy. Concomitantly, a 35% increase of fasting and postprandial plasma C peptide levels occurred. The data suggest that the use of combined sulfonylurea and insulin therapy may be beneficial to type II diabetic patients with residual insulin secretion and poor glycemic control under insulin therapy alone. SN - 0338-1684 UR - https://www.unboundmedicine.com/medline/citation/3084315/Effect_of_glibenclamide_in_insulin_treated_diabetic_patients_with_a_residual_insulin_secretion_ DB - PRIME DP - Unbound Medicine ER -